MCID: BLL006
MIFTS: 64

Bullous Pemphigoid

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Bullous Pemphigoid

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid 12 77 54 60 15 17 74
Senile Dermatitis Herpetiformis 54 74
Benign Pemphigus 54 74
Pemphigoid 54 38
Pemphigoid, Susceptibility to 13
Pemphigoid, Bullous 45
Pemphigoid Bullous 56
Old Age Pemphigus 54
Parapemphigus 54

Characteristics:

Orphanet epidemiological data:

60
bullous pemphigoid
Age of onset: All ages;

Classifications:

Orphanet: 60  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8506
KEGG 38 H01650
ICD9CM 36 694.5
MeSH 45 D010391
SNOMED-CT 69 77090002 86142006
ICD10 34 L12 L12.0 L12.9
MESH via Orphanet 46 D010391
ICD10 via Orphanet 35 L12.0
UMLS via Orphanet 75 C0030805
Orphanet 60 ORPHA703

Summaries for Bullous Pemphigoid

NIH Rare Diseases : 54 Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. In some people, the mouth or genitals are also affected. The blisters may break open and form ulcers or open sores. Bullous pemphigoid usually occurs in older persons and is rare in young people. Symptoms may come and go. In most patients, the condition goes away after several years. Bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake. Treatment may include corticosteroids taken by mouth or applied to the skin. Medicines that suppress the immune system may also be prescribed. For some, antibiotics in the tetracycline family are useful.

MalaCards based summary : Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to lichen planus pemphigoides and lichen planus. An important gene associated with Bullous Pemphigoid is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Prednisone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lung, and related phenotypes are diabetes mellitus and abnormal blistering of the skin

Disease Ontology : 12 An autoimmune disease of skin and connective tissue characterized by large blisters.

Wikipedia : 77 Bullous pemphigoid is an autoimmune pruritic skin disease preferentially in elderly people, that may... more...

Related Diseases for Bullous Pemphigoid

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 33.1 COL17A1 DST ITGB4
2 lichen planus 31.1 COL17A1 DSG3 DST
3 epidermolysis bullosa acquisita 31.1 COL17A1 DST ITGB4 LAMA3
4 pemphigoid gestationis 31.0 CCL11 COL17A1 DST HLA-DRB1 IL5
5 linear iga disease 31.0 COL17A1 DST ITGB4
6 dermatitis 30.8 CCL11 CCL17 DSG1 IL5
7 lichen sclerosus 30.7 COL17A1 HLA-DQB1 HLA-DRB1
8 pemphigus 30.6 COL17A1 DSG1 DSG3 DSP DST EVPL
9 cicatricial pemphigoid 30.6 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMC2
10 ocular cicatricial pemphigoid 30.6 HLA-DQB1 HLA-DRB1 ITGA6 ITGB4 RNASE3
11 conjunctivitis 30.5 CCL11 IL5 RNASE3
12 esophagitis 30.4 CCL11 DSG1 IL5
13 herpetiform pemphigus 30.4 DSG1 DSG3 DST
14 epidermolysis bullosa simplex 30.4 COL17A1 DST ITGB4 PLEC
15 gastroenteritis 30.4 CCL11 IL5 RNASE3
16 chronic eosinophilic pneumonia 30.4 CCL11 IL5 RNASE3
17 autoimmune disease 30.3 COL17A1 DSG1 HLA-DQB1 HLA-DRB1 TNFSF13B
18 hypereosinophilic syndrome 30.2 CCL11 CCL17 IL5 RNASE3
19 pemphigus foliaceus 30.0 DSG1 DSG3 DST EVPL HLA-DRB1 PPL
20 chronic conjunctivitis 29.9 CCL11 IL5 RNASE3
21 pemphigus vulgaris 29.9 DSG1 DSG3 DSP DST EVPL HLA-DRB1
22 epidermolysis bullosa 29.9 COL17A1 DSP DST ITGA6 ITGB4 LAMA3
23 bronchiolitis 29.9 CCL11 IL5 RNASE3
24 dermatitis, atopic 29.8 CCL11 CCL17 IL5 RNASE3
25 churg-strauss syndrome 29.8 CCL17 IL5 RNASE3
26 pemphigus vegetans 29.8 DSG1 PPL
27 junctional epidermolysis bullosa 29.7 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
28 eosinophilic pneumonia 29.7 CCL11 CCL17 IL5 RNASE3
29 allergic hypersensitivity disease 29.6 CCL11 CCL17 IL5 RNASE3
30 epidermolysis bullosa, junctional, non-herlitz type 29.6 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
31 atopic keratoconjunctivitis 29.5 IL5 RNASE3
32 keratoconjunctivitis 29.3 CCL11 CCL17 IL5 RNASE3
33 paraneoplastic pemphigus 29.0 COL17A1 DSG1 DSG3 DSP DST EVPL
34 subcorneal pustular dermatosis 28.9 CCL17 COL17A1 DSG1 DSG3 DST EVPL
35 cellulitis 28.5 COL17A1 DSG1 DSG3 DSP DST IL5
36 skin disease 27.2 CCL11 CCL17 COL17A1 DSG1 DSG3 DSP
37 brunsting-perry syndrome 11.9
38 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
39 autoimmune disease, multisystem, infantile-onset, 2 11.3
40 recessive dystrophic epidermolysis bullosa-generalized other 11.3
41 pseudomembranous conjunctivitis 11.1
42 psoriasis 10.8
43 pemphigus vulgaris, familial 10.7
44 dermatitis herpetiformis, familial 10.7
45 dermatitis herpetiformis 10.7
46 bowenoid papulosis 10.6
47 lupus erythematosus 10.6
48 multiple sclerosis 10.5
49 melanoma 10.5
50 scabies 10.5

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Pemphigus Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:



Diseases related to Bullous Pemphigoid

Symptoms & Phenotypes for Bullous Pemphigoid

Human phenotypes related to Bullous Pemphigoid:

60 33 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 60 33 hallmark (90%) Very frequent (99-80%) HP:0000819
2 abnormal blistering of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0008066
3 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
4 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
5 recurrent infections 60 33 hallmark (90%) Very frequent (99-80%) HP:0002719
6 erythema 60 33 hallmark (90%) Very frequent (99-80%) HP:0010783
7 macule 60 33 hallmark (90%) Very frequent (99-80%) HP:0012733
8 eczema 60 33 hallmark (90%) Very frequent (99-80%) HP:0000964
9 urticaria 60 33 hallmark (90%) Very frequent (99-80%) HP:0001025
10 psoriasiform dermatitis 60 33 frequent (33%) Frequent (79-30%) HP:0003765

GenomeRNAi Phenotypes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 CCL11 CCL17 COL17A1 DSG1 DSG3 DSP

MGI Mouse Phenotypes related to Bullous Pemphigoid:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 DSG1 DSG3 DSP HLA-DQB1 IL5 ITGA6
2 digestive/alimentary MP:0005381 9.97 DSG3 DSP HLA-DQB1 IL5 ITGA6 ITGB4
3 craniofacial MP:0005382 9.91 DSG3 DSP ITGA6 ITGB4 LAMA3 LAMB3
4 immune system MP:0005387 9.9 CCL11 CCL17 DSG3 HLA-DQB1 IL5 ITGA6
5 integument MP:0010771 9.65 DSG1 DSG3 DSP EVPL ITGA6 ITGB4
6 respiratory system MP:0005388 9.28 CCL11 DSG3 HLA-DQB1 IL5 ITGA6 ITGB4

Drugs & Therapeutics for Bullous Pemphigoid

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 25122-46-7, 25122-41-2 5311051 32798
3
Omalizumab Approved, Investigational Phase 4 242138-07-4
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8 glucocorticoids Phase 4,Phase 3,Phase 2
9 Hormones Phase 4,Phase 3,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
12 Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Antineoplastic Agents, Hormonal Phase 4
14 Respiratory System Agents Phase 4
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Asthmatic Agents Phase 4
17 Anti-Allergic Agents Phase 4
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
19 Immunoglobulin E Phase 4
20 Vitamins Phase 4,Phase 1,Phase 2
21 Calciferol Phase 4
22 Calcium, Dietary Phase 4
23 Hydrocortisone 17-butyrate 21-propionate Phase 4
24 Hydrocortisone hemisuccinate Phase 4
25
leucovorin Approved Phase 3 58-05-9 143 6006
26
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
27
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
28
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
29
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
31 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
32 Vitamin B9 Phase 3,Phase 1,Phase 2
33 Nucleic Acid Synthesis Inhibitors Phase 3
34 Antirheumatic Agents Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2
36 Immunologic Factors Phase 3,Phase 2,Phase 1
37 Vitamin B Complex Phase 3,Phase 1,Phase 2
38 Folic Acid Antagonists Phase 3
39 Antimetabolites, Antineoplastic Phase 3,Phase 2
40 Folate Phase 3,Phase 1,Phase 2
41 Antimetabolites Phase 3,Phase 2,Phase 1
42 Anti-Infective Agents Phase 3,Phase 2
43 Anti-Bacterial Agents Phase 3,Phase 2
44 Antineoplastic Agents, Immunological Phase 3,Phase 1,Phase 2
45 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1
46 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1
47 gamma-Globulins Phase 3,Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 3,Phase 2
49 Antitubercular Agents Phase 3,Phase 2
50 Alkylating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
2 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
3 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Not yet recruiting NCT03926377 Phase 4
4 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
5 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
6 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
7 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Completed NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
8 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
10 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
11 Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
12 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
13 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
14 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Completed NCT02226146 Phase 2
15 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
16 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
17 Ixekizumab in the Treatment of Bullous Pemphigoid Recruiting NCT03099538 Phase 2 Ixekizumab
18 A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Recruiting NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
19 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
20 Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
21 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
22 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
23 The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
24 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
25 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders Recruiting NCT02502903 Phase 1 BIV009
26 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
27 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
28 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079 Not Applicable
29 Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
30 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
31 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675 Not Applicable
32 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Unknown status NCT02872584 Prednisone
33 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
34 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
35 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
36 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067
37 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
38 Register of Autoimmune Bullous Dermatoses Completed NCT02899923
39 Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Completed NCT00116090
40 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
41 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Completed NCT00357071
42 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? Recruiting NCT03636763 data report
43 Cytokines in Blister Fluids of Bullous Pemphigoid (BP) Recruiting NCT03856840
44 Autoimmune Blistering Diseases Study Recruiting NCT02753777
45 Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients Recruiting NCT03129308
46 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313 Not Applicable
47 Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069 Not Applicable
48 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
49 Trichoscopy in Diagnosis of Immunobollous Diseases Not yet recruiting NCT03478072
50 Histology Evaluation of Radiofrequency Ablation Not yet recruiting NCT03947723 Not Applicable

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: pemphigoid, bullous

Genetic Tests for Bullous Pemphigoid

Anatomical Context for Bullous Pemphigoid

MalaCards organs/tissues related to Bullous Pemphigoid:

42
Skin, T Cells, Lung, Breast, Eye, B Cells, Neutrophil

Publications for Bullous Pemphigoid

Articles related to Bullous Pemphigoid:

(show top 50) (show all 2200)
# Title Authors Year
1
Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report. ( 30882350 )
2019
2
Drugs used for neurological and psychiatric conditions increase the risk of bullous pemphigoid: a case-control study. ( 30771421 )
2019
3
Bullous Pemphigoid with Atypical Skin Lesions and Acute Interstitial Nephritis: A Case Report and Focused Literature Review. ( 30773528 )
2019
4
The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center. ( 30784240 )
2019
5
Bullous Pemphigoid IgG Induces Cell Dysfunction and Enhances the Motility of Epidermal Keratinocytes via Rac1/Proteasome Activation. ( 30809225 )
2019
6
Bullous pemphigoid and cancer in Taiwan. ( 30821366 )
2019
7
Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab. ( 30827944 )
2019
8
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. ( 30837635 )
2019
9
Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. ( 30844553 )
2019
10
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. ( 30848289 )
2019
11
Exacerbation of well-controlled bullous pemphigoid by the administration of a dipeptidyl peptidase-4 inhibitor: a case report. ( 30859617 )
2019
12
Presence of anti-BP180 and anti-BP230 in the CSF of patients with bullous pemphigoid and neurologic disease: is there any intrathecal synthesis? ( 30883687 )
2019
13
Bullous pemphigoid: more than one disease? ( 30891848 )
2019
14
Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. ( 30904079 )
2019
15
Rituximab Therapy in Patients with Bullous Pemphigoid: A Retrospective Study of 20 Patients. ( 30923002 )
2019
16
Circulating Bullous Pemphigoid Autoantibodies in the Setting of Negative Direct Immunofluorescence Findings for Bullous Pemphigoid: A Single-Center Retrospective Review. ( 30928465 )
2019
17
Association between serum 25-hydroxyvitamin D concentration and severity of first-diagnosed bullous pemphigoid in older adults. ( 30933743 )
2019
18
Localised bullous pemphigoid overlying knee arthroplasty: a diagnostic challenge. ( 30954955 )
2019
19
Milia within resolving bullous pemphigoid lesions. ( 30956594 )
2019
20
A new indirect immunofluorescence BIOCHIP method for the serological diagnosis of bullous pemphigoid: A review of literature. ( 30968398 )
2019
21
Alogliptin-induced bullous pemphigoid associated with HLA-DQB1*03:01: a case report. ( 30968950 )
2019
22
A case of atezolizumab-induced photodistributed bullous pemphigoid. ( 30977954 )
2019
23
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology. ( 30989811 )
2019
24
Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. ( 30997084 )
2019
25
Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid. ( 31001258 )
2019
26
REPLY to MS#JAAD-D-19-0054 "Bullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?" ( 31002849 )
2019
27
Bullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions? ( 31004730 )
2019
28
Integrin α6β4 Recognition of a Linear Motif of Bullous Pemphigoid Antigen BP230 Controls Its Recruitment to Hemidesmosomes. ( 31006587 )
2019
29
Pembrolizumab-induced bullous pemphigoid. ( 31008169 )
2019
30
NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay. ( 31019514 )
2019
31
Reorganization of serum analysis tools for the diagnosis of bullous pemphigoid. ( 31025727 )
2019
32
Alzheimer's disease identified in a patient with bullous pemphigoid by dementia screening scales. ( 31058670 )
2019
33
Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan. ( 31062428 )
2019
34
C4d immunohistochemical stain of formalin-fixed paraffin-embedded tissue as a sensitive method in the diagnosis of bullous pemphigoid. ( 31069830 )
2019
35
Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA Adverse Event Reporting System. ( 31088310 )
2019
36
Bullous pemphigoid. ( 31090818 )
2019
37
Bullous pemphigoid associated with psoriasis: a good response to methotrexate. ( 31090831 )
2019
38
Circulating bullous pemphigoid 180 autoantibody can be detected in a wide spectrum of patients with other dermatologic conditions: A cross-sectional study. ( 29906544 )
2019
39
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. ( 29920976 )
2019
40
Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. ( 29963683 )
2019
41
Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. ( 30129048 )
2019
42
Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies. ( 30141189 )
2019
43
Early-onset neutropenia after rituximab therapy for bullous pemphigoid. ( 30151931 )
2019
44
A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid. ( 30188568 )
2019
45
Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study. ( 30216411 )
2019
46
IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. ( 30219389 )
2019
47
Bullous pemphigoid in a 3-month-old infant after vaccination. ( 30267442 )
2019
48
Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid. ( 30315657 )
2019
49
Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up. ( 30350359 )
2019
50
Mortality and risk factors among Israeli bullous pemphigoid patients. ( 30382340 )
2019

Variations for Bullous Pemphigoid

Expression for Bullous Pemphigoid

Search GEO for disease gene expression data for Bullous Pemphigoid.

Pathways for Bullous Pemphigoid

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CCL11 CCL17 COL17A1 DSP IL5 ITGA6
2
Show member pathways
13.31 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
3
Show member pathways
12.99 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
4
Show member pathways
12.81 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5
Show member pathways
12.79 CCL11 HLA-DQB1 HLA-DRB1 IL5 RNASE3 TNFSF13B
6 12.76 IL5 ITGA6 LAMA3 LAMB3 LAMC2
7
Show member pathways
12.72 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
8
Show member pathways
12.58 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
9
Show member pathways
12.41 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
10
Show member pathways
12.39 DSG1 DSG3 DSP EVPL PPL
11
Show member pathways
12.31 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
12
Show member pathways
12.18 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
13
Show member pathways
12.07 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
14
Show member pathways
12.07 HLA-DQB1 HLA-DRB1 ITGA6 LAMA3 LAMB3 LAMC2
15
Show member pathways
12.02 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
16 11.94 DSP ITGA6 ITGB4 PLEC
17
Show member pathways
11.88 DSG1 DSG3 DSP PLEC
18
Show member pathways
11.84 DSP DST EVPL PLEC PPL
19 11.8 LAMA3 LAMB3 LAMC2
20 11.78 HLA-DQB1 HLA-DRB1 IL5 ITGA6
21 11.77 HLA-DQB1 HLA-DRB1 TNFSF13B
22 11.75 ITGA6 LAMA3 LAMB3 LAMC2
23 11.6 DSG1 HLA-DQB1 HLA-DRB1
24 11.59 CCL11 CCL17 IL5
25 11.59 CCL11 DSP IL5
26 11.57 LAMA3 LAMB3 LAMC2
27 11.42 CCL11 CCL17 IL5
28 11.19 COL17A1 ITGA6 ITGB4
29 11.13 CCL11 CCL17 IL5 TNFSF13B
30 10.23 CCL11 CCL17 COL17A1 IL5 ITGA6 ITGB4

GO Terms for Bullous Pemphigoid

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSG1 DSG3 DSP DST EVPL
2 intermediate filament GO:0005882 9.77 DSP DST EVPL PLEC PPL
3 cornified envelope GO:0001533 9.65 DSG1 DSG3 DSP EVPL PPL
4 basement membrane GO:0005604 9.63 COL17A1 DST ITGA6 LAMA3 LAMB3 LAMC2
5 MHC class II protein complex GO:0042613 9.48 HLA-DQB1 HLA-DRB1
6 laminin-5 complex GO:0005610 9.4 LAMA3 LAMB3
7 desmosome GO:0030057 9.35 DSG1 DSG3 DSP EVPL PPL
8 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC
9 plasma membrane GO:0005886 10.23 COL17A1 DSG1 DSG3 DSP DST HLA-DQB1
10 extracellular region GO:0005576 10.09 CCL11 CCL17 COL17A1 IL5 LAMA3 LAMB3

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 CCL11 CCL17 HLA-DQB1 HLA-DRB1 IL5 TNFSF13B
2 cell adhesion GO:0007155 9.91 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 keratinization GO:0031424 9.83 DSG1 DSG3 DSP EVPL PPL
4 cornification GO:0070268 9.8 DSG1 DSG3 DSP EVPL PPL
5 extracellular matrix organization GO:0030198 9.8 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
6 wound healing GO:0042060 9.77 DSP DST EVPL PLEC PPL
7 cell-matrix adhesion GO:0007160 9.73 COL17A1 ITGA6 ITGB4
8 integrin-mediated signaling pathway GO:0007229 9.72 DST ITGA6 ITGB4
9 skin development GO:0043588 9.67 DSP ITGA6 ITGB4
10 epidermis development GO:0008544 9.63 COL17A1 DSP EVPL LAMA3 LAMB3 LAMC2
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.57 HLA-DQB1 HLA-DRB1
12 amelogenesis GO:0097186 9.54 ITGA6 ITGB4
13 nail development GO:0035878 9.52 ITGA6 ITGB4
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.51 HLA-DQB1 HLA-DRB1
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.48 HLA-DQB1 HLA-DRB1
16 intermediate filament cytoskeleton organization GO:0045104 9.35 DSP DST EVPL PLEC PPL
17 hemidesmosome assembly GO:0031581 9.23 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.71 EVPL ITGA6 PLEC PPL
2 structural constituent of cytoskeleton GO:0005200 9.54 DSP PLEC PPL
3 cytokine activity GO:0005125 9.46 CCL11 CCL17 IL5 TNFSF13B
4 insulin-like growth factor I binding GO:0031994 9.32 ITGA6 ITGB4
5 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
6 structural molecule activity GO:0005198 9.17 DSP DST EVPL LAMA3 LAMB3 PLEC
7 neuregulin binding GO:0038132 8.96 ITGA6 ITGB4

Sources for Bullous Pemphigoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....